Loading organizations...
Loading organizations...
Xicheng Zhiyuan operates as a private equity firm, building and managing a diversified investment portfolio. Its core activity involves providing capital and strategic guidance to promising growth-stage companies. The firm focuses on identifying value opportunities within specific sectors, deploying funds to foster innovation and expansion across its investee entities.
Established in 2021, Xicheng Zhiyuan was founded by partners Fan Daoyuan, Xu Junming, Wang Bo, and Michael H Wang. Their collective insight highlighted the potential for targeted capital combined with active management to unlock significant value in the evolving market, leading to the formation of the firm.
Xicheng Zhiyuan primarily serves companies seeking substantial capital for development, alongside institutional investors aiming for strategic private market exposure. The firm envisions cultivating a robust ecosystem of successful enterprises, driving long-term value creation by acting as a pivotal partner in their growth journeys.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 4, 2024 | Convalife Pharmaceuticals | $100.0M Series C | Xicheng Zhiyuan | — |